Lutetium Lu 177 Vipivotide Tetraxetan: First Approval

This article summarizes the milestones in the development of Lutetium Lu 177 vipivotide tetraxetan leading to this first approval as a therapeutic radioligand for mCRPC.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research